Online inquiry

IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11172MR)

This product GTTS-WQ11172MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNFRSF4 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_003327.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7293
UniProt ID P43489
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11172MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ13416MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ1267MR IVTScrip™ mRNA-Anti-EGFR, ABT-414(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABT-414
GTTS-WQ4225MR IVTScrip™ mRNA-Anti-Factor IX substitute, BIIB029(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA BIIB029
GTTS-WQ7325MR IVTScrip™ mRNA-Anti-FGFR2, FPA-144(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA FPA-144
GTTS-WQ10099MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LA480
GTTS-WQ11505MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MetMAb
GTTS-WQ3915MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BCD-135
GTTS-WQ4612MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986015
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW